1. Home
  2. MLYS vs ESQ Comparison

MLYS vs ESQ Comparison

Compare MLYS & ESQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$23.61

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Logo Esquire Financial Holdings Inc.

ESQ

Esquire Financial Holdings Inc.

HOLD

Current Price

$106.98

Market Cap

910.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLYS
ESQ
Founded
2019
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Commercial Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
910.9M
IPO Year
2023
2017

Fundamental Metrics

Financial Performance
Metric
MLYS
ESQ
Price
$23.61
$106.98
Analyst Decision
Strong Buy
Buy
Analyst Count
6
3
Target Price
$48.67
$120.33
AVG Volume (30 Days)
1.1M
75.5K
Earning Date
03-12-2026
04-23-2026
Dividend Yield
N/A
0.75%
EPS Growth
37.43
14.20
EPS
N/A
5.87
Revenue
N/A
N/A
Revenue This Year
N/A
$28.65
Revenue Next Year
N/A
$4.95
P/E Ratio
N/A
$18.16
Revenue Growth
N/A
N/A
52 Week Low
$10.44
$69.14
52 Week High
$47.65
$119.86

Technical Indicators

Market Signals
Indicator
MLYS
ESQ
Relative Strength Index (RSI) 36.30 50.75
Support Level $12.98 $91.62
Resistance Level $31.09 $112.17
Average True Range (ATR) 1.56 3.89
MACD -0.06 0.36
Stochastic Oscillator 12.94 50.92

Price Performance

Historical Comparison
MLYS
ESQ

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About ESQ Esquire Financial Holdings Inc.

Esquire Financial Holdings Inc is a financial holding company operating as a full service commercial bank. It serves the financial needs of the litigation industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The bank offers tailored financial and payment processing solutions to the litigation community and their clients as well as dynamic and flexible payment processing solutions to small business owners. It operates in one operating segment, that of community banking.

Share on Social Networks: